X0306 4 2017-02-28 0000885725 BOSTON SCIENTIFIC CORP BSX 0001529708 Nanavaty Maulik 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752-1234 1 SVP & Pres, Neuromodulation Common Stock 2017-02-28 4 A 0 26758.0000 0.0000 A 216540.0000 D Common Stock 2017-02-28 4 M 0 3383.0000 0.0000 A 219923.0000 D Common Stock 2017-02-28 4 F 0 12832.0000 24.5500 D 207091.0000 D Deferred Stock Units 2017-02-28 4 M 0 3383.0000 0.0000 D 2018-02-28 Common Stock 3383.0000 3383.0000 D Deferred Stock Units 2017-02-28 4 A 0 8146.0000 0.0000 A 2022-02-28 Common Stock 8146.0000 8146.0000 D Performance Share Units 2017-02-28 4 A 0 10750.0000 0.0000 A 2018-12-31 2018-12-31 Common Stock 10750.0000 10750.0000 D Stock Option (Right to Buy) 24.5500 2017-02-28 4 A 0 26350.0000 0.0000 A 2027-02-28 Common Stock 26350.0000 26350.0000 D On February 24, 2014, the reporting person was awarded a target number of performance share units under the Company's 2014 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person was based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2016 and was subject to the completion of the concurrent three-year individual service period. On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018. Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. /s/ Vance R. Brown, Attorney-in-fact 2017-03-01